Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Total Sales of 26 Japan Drug Makers Up 6.1% in H1; Shionogi Nets Largest Growth
December 12, 2023
- Sobi Eyes Japan Approval of 4 Rare Disease Drugs in 5 Years: Local Chief
December 12, 2023
- Astellas’ Hot Flash Drug Bags European Nod
December 12, 2023
- Lenvima-Keytruda Combo Misses Goal in 1st Line Endometrial Cancer
December 12, 2023
- NEC Harnessing AI Prowess to Pursue Global Players in Cancer Vaccine Race
December 11, 2023
- KM, Meiji Initiate PIII Pediatric Trial for XBB.1.5-Adapted COVID Vaccine
December 8, 2023
- Pivlaz Approved in South Korea, Set for Launch in Early 2025
December 8, 2023
- Japan Ethical Drug Sales Up 8.4% in October: Crecon
December 8, 2023
- Keytruda Scores No. 1 in Japan Sales Ranking in November: Encise
December 8, 2023
- Daiichi Sankyo, Novartis Settle Patent Infringement Dispute Over Tafinlar
December 7, 2023
- CSL Launches Home Delivery Service for HAE Drug Berinert
December 7, 2023
- Abecma Approved for Earlier Lines of MM Therapy in Japan: BMS
December 7, 2023
- Pfizer to Cut Ties with 3 Regional Wholesalers, Further Narrowing Expected
December 5, 2023
- Shionogi Hooks Up with Life Science VC AN Venture Partners
December 5, 2023
- Preliminary Injunction for Sprycel Generic “Extremely Unjust”: Sawai
December 5, 2023
- Ono Doubles Investment in Corporate Venture Fund to US$200 Million
December 4, 2023
- Padcev/Keytruda Combo Gets FDA Priority Review for Bladder Cancer
December 4, 2023
- Torii, BioCryst Revise Deal for HAE Drug Orladeyo in Japan
December 1, 2023
- Eisai Unit Joins Hands with Thai Authorities on Dementia Drug Access
December 1, 2023
- Mitsubishi Tanabe’s NMOSD Drug Uplizna Now Available in Taiwan
December 1, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…